ArticleAdvanced healthcare materials2026
Wearable OLED-Assisted Photodynamic Cancer Therapy Using Chlorin e6-Loaded Pluronic Nanocapsules as Photosensitizers.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Photodynamic therapy (PDT) is a minimally invasive cancer treatment strategy. Despite numerous studies confirming its potential advantages, the clinical translation of this technique remains limited owing to the impracticality of using conventional light sources and the instability of photosensitizers. This study presents a novel PDT approach that utilizes organic light-emitting diodes (OLEDs) as compact, low-thermal, wearable, and flexible light sources to activate chlorin e6 (Ce6)-loaded Pluronic nanocapsules (Ce6/Plu NCs) for anticancer therapy. Here, different types of Pluronic polymers are used and optimized to synthesize ∼120 nm-diameter Ce6/Plu NCs. Among the formulated systems, the Ce6/PP123 NCs show optimal spectral characteristics and the highest therapeutic efficacy in vitro, and efficient tumor accumulation after intravenous injection and significant antitumor efficacy upon OLED irradiation with minimal off-target toxicity in vivo. Tissue-attachable OLEDs for PDT can be placed in close proximity to tumor tissue for efficient light delivery. The combination of the Ce6/PP123 NCs with a novel wearable OLED is a promising platform for effective and safe PDT in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.